Presentation is loading. Please wait.

Presentation is loading. Please wait.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Published byکيانا فرجی Modified over 5 years ago

Similar presentations

Presentation on theme: "Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause."— Presentation transcript:

1 Recurrence pattern after initial treatment of brain metastases and cause of death.
Recurrence pattern after initial treatment of brain metastases and cause of death. (A) Frequency of extracranial progression after initial treatment of BM according to primary tumour type (B) Frequency of intracranial progression after initial treatment of BM according to primary tumour type (C) Disease status in the end of life period (D) Disease status in the end of life period according to primary tumour type. Anna S Berghoff et al. ESMO Open 2016;1:e000024 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause."

Similar presentations

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.
A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,

A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,
Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).

Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)
Flow chart of the used methodology adapted from Moher et al

Flow chart of the used methodology adapted from Moher et al
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
Overview of the QTWiST method

Overview of the QTWiST method
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.
PRISMA study flow diagram

PRISMA study flow diagram
(A) Number of KRAS mutations detected by mutation concentration by each technology with 100 copies mutant allele frequency. (A) Number of KRAS mutations.

(A) Number of KRAS mutations detected by mutation concentration by each technology with 100 copies mutant allele frequency. (A) Number of KRAS mutations.
Methods distribution among the three EQAs

Methods distribution among the three EQAs
Changes in haemoglobin over the course of the treatment in a patient with chronic myeloid leukaemia who developed pure red cell aplasia secondary to imatinib.

Changes in haemoglobin over the course of the treatment in a patient with chronic myeloid leukaemia who developed pure red cell aplasia secondary to imatinib.
Plot with best overall response and study duration.

Plot with best overall response and study duration.
Patients represented by 441 physicians surveyed from 19 countries, depicted in the patient journey from diagnosis to ensuing treatment with ADT. ADT, androgen.

Patients represented by 441 physicians surveyed from 19 countries, depicted in the patient journey from diagnosis to ensuing treatment with ADT. ADT, androgen.

Similar presentations

Ads by Google